1-4 of 4
Jim Cassidy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

Axel-R. Hanauske, Jim Cassidy, Javier Sastre, Claus Bolling, Robert J. Jones, Ashok Rakhit, Scott Fettner, Ulrich Brennscheidt, Andrea Feyereislova, Eduardo Díaz-Rubio
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 523–531.
https://doi.org/10.1158/1078-0432.CCR-06-1627
Published: 25 January 2007
View article titled, Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors

Ramon Salazar, Donald Bissett, Chris Twelves, Lars Breimer, Mark DeMario, Sophia Campbell, Jay Zhi, Steve Ritland, Jim Cassidy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4374–4382.
https://doi.org/10.1158/1078-0432.CCR-04-0135
Published: 06 July 2004
View article titled, A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Ro 31-7453 Given as a 7- or 14-Day Oral Twice Daily Schedule Every 4 Weeks in Patients with Solid Tumors in another window
Journal Articles

Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites

Chris Twelves, Robert Glynne-Jones, Jim Cassidy, Johannes Schüller, Timothy Goggin, Brigitte Roos, Ludger Banken, Masahiro Utoh, Erhard Weidekamm, Bruno Reigner
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1696–1702.
Published: 01 July 1999
View article titled, Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites
Open the PDF for Effect of Hepatic Dysfunction due to Liver Metastases on the Pharmacokinetics of Capecitabine and Its Metabolites in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

Paul A. Vasey, Stan B. Kaye, Rosemary Morrison, Chris Twelves, Peter Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, Tom E. Hilditch, Tom Murray, Sally Burtles, D. Fraier, E. Frigerio, Jim Cassidy, on behalf of the Cancer Research Campaign Phase I/II Committee
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 83–94.
Published: 01 January 1999
View article titled, Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
Open the PDF for Phase I Clinical and Pharmacokinetic Study of PK1 [<em>N</em>-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates in another window